EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL
Identifieur interne : 000A18 ( Main/Corpus ); précédent : 000A17; suivant : 000A19EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL
Auteurs : Jes GerlachSource :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1976-01.
Abstract
Twenty patients with paralysis agitans took part in a double‐blind, cross‐over investigation of CB 154 (2‐bromo‐alpha‐ergocryptine) and Madopar® (L‐Dopa + benserazid (a peripheral decarboxylase inhibitor), dose ratio 4:1). Each treatment phase lasted for 8 weeks. Modapar was found to be significantly superior to CB 154 in the treatment of the Parkinson state as a whole (Webster total score) and the individual symptoms of hypokinesia, rigidity and tremor. Compared with pretreatment score, CB 154 had a weak, but significant effect on tremor, but not on the Webster total score, hypokinesia and rigidity. the effect of CB 154, however, varied: four patients preferred CB 154 to Madopar on account of its satisfactory therapeutic effect and fewer side‐effects (“on‐off” phenomena, hyperkinesia, psychiatric complications); other patients showed neither therapeutic effect nor side‐effects of CB 154, which in some cases may be related to too low a dose‐level of CB 154 (median 30 mg daily, range 20–60 mg). In the four cases first mentioned which showed a good effect of CB 154, the ratio between the dose of CB 154 and the dose of L‐Dopa (in Madopar) was 3.5–10 mg/100 mg, i.e. in certain cases it must be assumed that the maximum dose of CB 154 lies around 120 mg daily.
Url:
DOI: 10.1111/j.1600-0404.1976.tb04337.x
Links to Exploration step
ISTEX:12FB09FA70D0DDF0FBE1F765EB368C1299501042Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL</title><author><name sortKey="Gerlach, Jes" sort="Gerlach, Jes" uniqKey="Gerlach J" first="Jes" last="Gerlach">Jes Gerlach</name><affiliation><mods:affiliation>Kommunehospitalet, Neurological Department, Copenhagen, Denmark.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:12FB09FA70D0DDF0FBE1F765EB368C1299501042</idno><date when="1976" year="1976">1976</date><idno type="doi">10.1111/j.1600-0404.1976.tb04337.x</idno><idno type="url">https://api.istex.fr/document/12FB09FA70D0DDF0FBE1F765EB368C1299501042/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL</title><author><name sortKey="Gerlach, Jes" sort="Gerlach, Jes" uniqKey="Gerlach J" first="Jes" last="Gerlach">Jes Gerlach</name><affiliation><mods:affiliation>Kommunehospitalet, Neurological Department, Copenhagen, Denmark.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1976-01">1976-01</date><biblScope unit="volume">53</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="189">189</biblScope><biblScope unit="page" to="200">200</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">12FB09FA70D0DDF0FBE1F765EB368C1299501042</idno><idno type="DOI">10.1111/j.1600-0404.1976.tb04337.x</idno><idno type="ArticleID">ANE189</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Twenty patients with paralysis agitans took part in a double‐blind, cross‐over investigation of CB 154 (2‐bromo‐alpha‐ergocryptine) and Madopar® (L‐Dopa + benserazid (a peripheral decarboxylase inhibitor), dose ratio 4:1). Each treatment phase lasted for 8 weeks. Modapar was found to be significantly superior to CB 154 in the treatment of the Parkinson state as a whole (Webster total score) and the individual symptoms of hypokinesia, rigidity and tremor. Compared with pretreatment score, CB 154 had a weak, but significant effect on tremor, but not on the Webster total score, hypokinesia and rigidity. the effect of CB 154, however, varied: four patients preferred CB 154 to Madopar on account of its satisfactory therapeutic effect and fewer side‐effects (“on‐off” phenomena, hyperkinesia, psychiatric complications); other patients showed neither therapeutic effect nor side‐effects of CB 154, which in some cases may be related to too low a dose‐level of CB 154 (median 30 mg daily, range 20–60 mg). In the four cases first mentioned which showed a good effect of CB 154, the ratio between the dose of CB 154 and the dose of L‐Dopa (in Madopar) was 3.5–10 mg/100 mg, i.e. in certain cases it must be assumed that the maximum dose of CB 154 lies around 120 mg daily.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Jes Gerlach</name><affiliations><json:string>Kommunehospitalet, Neurological Department, Copenhagen, Denmark.</json:string></affiliations></json:item></author><articleId><json:string>ANE189</json:string></articleId><language><json:string>eng</json:string></language><abstract>Twenty patients with paralysis agitans took part in a double‐blind, cross‐over investigation of CB 154 (2‐bromo‐alpha‐ergocryptine) and Madopar® (L‐Dopa + benserazid (a peripheral decarboxylase inhibitor), dose ratio 4:1). Each treatment phase lasted for 8 weeks. Modapar was found to be significantly superior to CB 154 in the treatment of the Parkinson state as a whole (Webster total score) and the individual symptoms of hypokinesia, rigidity and tremor. Compared with pretreatment score, CB 154 had a weak, but significant effect on tremor, but not on the Webster total score, hypokinesia and rigidity. the effect of CB 154, however, varied: four patients preferred CB 154 to Madopar on account of its satisfactory therapeutic effect and fewer side‐effects (“on‐off” phenomena, hyperkinesia, psychiatric complications); other patients showed neither therapeutic effect nor side‐effects of CB 154, which in some cases may be related to too low a dose‐level of CB 154 (median 30 mg daily, range 20–60 mg). In the four cases first mentioned which showed a good effect of CB 154, the ratio between the dose of CB 154 and the dose of L‐Dopa (in Madopar) was 3.5–10 mg/100 mg, i.e. in certain cases it must be assumed that the maximum dose of CB 154 lies around 120 mg daily.</abstract><qualityIndicators><score>7.643</score><pdfVersion>1.5</pdfVersion><pdfPageSize>435.6 x 669.84 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1274</abstractCharCount><pdfWordCount>4171</pdfWordCount><pdfCharCount>23611</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>206</abstractWordCount></qualityIndicators><title>EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL</title><genre><json:string>article</json:string></genre><host><volume>53</volume><publisherId><json:string>ANE</json:string></publisherId><pages><total>12</total><last>200</last><first>189</first></pages><issn><json:string>0001-6314</json:string></issn><issue>3</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0404</json:string></eissn><title>Acta Neurologica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0404</json:string></doi></host><publicationDate>1976</publicationDate><copyrightDate>1976</copyrightDate><doi><json:string>10.1111/j.1600-0404.1976.tb04337.x</json:string></doi><id>12FB09FA70D0DDF0FBE1F765EB368C1299501042</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/12FB09FA70D0DDF0FBE1F765EB368C1299501042/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/12FB09FA70D0DDF0FBE1F765EB368C1299501042/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/12FB09FA70D0DDF0FBE1F765EB368C1299501042/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1976</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL</title><author><persName><forename type="first">Jes</forename><surname>Gerlach</surname></persName><note type="correspondence"><p>Correspondence: *J. Gerlach, M.D., 26, Ole Olsens Alle, DK‐2900 Hellerup, Denmark.</p></note><affiliation>Kommunehospitalet, Neurological Department, Copenhagen, Denmark.</affiliation></author></analytic><monogr><title level="j">Acta Neurologica Scandinavica</title><idno type="pISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><idno type="DOI">10.1111/(ISSN)1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1976-01"></date><biblScope unit="volume">53</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="189">189</biblScope><biblScope unit="page" to="200">200</biblScope></imprint></monogr><idno type="istex">12FB09FA70D0DDF0FBE1F765EB368C1299501042</idno><idno type="DOI">10.1111/j.1600-0404.1976.tb04337.x</idno><idno type="ArticleID">ANE189</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1976</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Twenty patients with paralysis agitans took part in a double‐blind, cross‐over investigation of CB 154 (2‐bromo‐alpha‐ergocryptine) and Madopar® (L‐Dopa + benserazid (a peripheral decarboxylase inhibitor), dose ratio 4:1). Each treatment phase lasted for 8 weeks. Modapar was found to be significantly superior to CB 154 in the treatment of the Parkinson state as a whole (Webster total score) and the individual symptoms of hypokinesia, rigidity and tremor. Compared with pretreatment score, CB 154 had a weak, but significant effect on tremor, but not on the Webster total score, hypokinesia and rigidity. the effect of CB 154, however, varied: four patients preferred CB 154 to Madopar on account of its satisfactory therapeutic effect and fewer side‐effects (“on‐off” phenomena, hyperkinesia, psychiatric complications); other patients showed neither therapeutic effect nor side‐effects of CB 154, which in some cases may be related to too low a dose‐level of CB 154 (median 30 mg daily, range 20–60 mg). In the four cases first mentioned which showed a good effect of CB 154, the ratio between the dose of CB 154 and the dose of L‐Dopa (in Madopar) was 3.5–10 mg/100 mg, i.e. in certain cases it must be assumed that the maximum dose of CB 154 lies around 120 mg daily.</p></abstract></profileDesc><revisionDesc><change when="1976-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/12FB09FA70D0DDF0FBE1F765EB368C1299501042/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0404</doi><issn type="print">0001-6314</issn><issn type="electronic">1600-0404</issn><idGroup><id type="product" value="ANE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA NEUROLOGICA SCANDINAVICA">Acta Neurologica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="01003"><doi origin="wiley">10.1111/ane.1976.53.issue-3</doi><numberingGroup><numbering type="journalVolume" number="53">53</numbering><numbering type="journalIssue" number="3">3</numbering></numberingGroup><coverDate startDate="1976-01">January 1976</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0018900" status="forIssue"><doi origin="wiley">10.1111/j.1600-0404.1976.tb04337.x</doi><idGroup><id type="unit" value="ANE189"></id></idGroup><countGroup><count type="pageTotal" number="12"></count></countGroup><titleGroup><title type="tocHeading1">Article</title></titleGroup><copyright>1976 Blackwell Munksgaard</copyright><eventGroup><event type="firstOnline" date="2009-01-29"></event><event type="publishedOnlineFinalForm" date="2009-01-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-10"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="189">189</numbering><numbering type="pageLast" number="200">200</numbering></numberingGroup><correspondenceTo>*J. Gerlach, M.D., 26, Ole Olsens Alle, DK‐2900 Hellerup, Denmark.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANE.ANE189.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received September 25, 1975.</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="30"></count><count type="linksCrossRef" number="2"></count></countGroup><titleGroup><title type="main">EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Jes</givenNames><familyName>Gerlach</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="DK"><unparsedAffiliation>Kommunehospitalet, Neurological Department, Copenhagen, Denmark.</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">ABSTRACT</title><p>Twenty patients with paralysis agitans took part in a double‐blind, cross‐over investigation of CB 154 (2‐bromo‐alpha‐ergocryptine) and Madopar® (L‐Dopa + benserazid (a peripheral decarboxylase inhibitor), dose ratio 4:1). Each treatment phase lasted for 8 weeks. Modapar was found to be significantly superior to CB 154 in the treatment of the Parkinson state as a whole (Webster total score) and the individual symptoms of hypokinesia, rigidity and tremor. Compared with pretreatment score, CB 154 had a weak, but significant effect on tremor, but not on the Webster total score, hypokinesia and rigidity. the effect of CB 154, however, varied: four patients preferred CB 154 to Madopar on account of its satisfactory therapeutic effect and fewer side‐effects (“on‐off” phenomena, hyperkinesia, psychiatric complications); other patients showed neither therapeutic effect nor side‐effects of CB 154, which in some cases may be related to too low a dose‐level of CB 154 (median 30 mg daily, range 20–60 mg). In the four cases first mentioned which showed a good effect of CB 154, the ratio between the dose of CB 154 and the dose of L‐Dopa (in Madopar) was 3.5–10 mg/100 mg, i.e. in certain cases it must be assumed that the maximum dose of CB 154 lies around 120 mg daily.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL</title></titleInfo><name type="personal"><namePart type="given">Jes</namePart><namePart type="family">Gerlach</namePart><affiliation>Kommunehospitalet, Neurological Department, Copenhagen, Denmark.</affiliation><description>Correspondence: *J. Gerlach, M.D., 26, Ole Olsens Alle, DK‐2900 Hellerup, Denmark.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1976-01</dateIssued><edition>Received September 25, 1975.</edition><copyrightDate encoding="w3cdtf">1976</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">30</extent></physicalDescription><abstract lang="en">Twenty patients with paralysis agitans took part in a double‐blind, cross‐over investigation of CB 154 (2‐bromo‐alpha‐ergocryptine) and Madopar® (L‐Dopa + benserazid (a peripheral decarboxylase inhibitor), dose ratio 4:1). Each treatment phase lasted for 8 weeks. Modapar was found to be significantly superior to CB 154 in the treatment of the Parkinson state as a whole (Webster total score) and the individual symptoms of hypokinesia, rigidity and tremor. Compared with pretreatment score, CB 154 had a weak, but significant effect on tremor, but not on the Webster total score, hypokinesia and rigidity. the effect of CB 154, however, varied: four patients preferred CB 154 to Madopar on account of its satisfactory therapeutic effect and fewer side‐effects (“on‐off” phenomena, hyperkinesia, psychiatric complications); other patients showed neither therapeutic effect nor side‐effects of CB 154, which in some cases may be related to too low a dose‐level of CB 154 (median 30 mg daily, range 20–60 mg). In the four cases first mentioned which showed a good effect of CB 154, the ratio between the dose of CB 154 and the dose of L‐Dopa (in Madopar) was 3.5–10 mg/100 mg, i.e. in certain cases it must be assumed that the maximum dose of CB 154 lies around 120 mg daily.</abstract><relatedItem type="host"><titleInfo><title>Acta Neurologica Scandinavica</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0001-6314</identifier><identifier type="eISSN">1600-0404</identifier><identifier type="DOI">10.1111/(ISSN)1600-0404</identifier><identifier type="PublisherID">ANE</identifier><part><date>1976</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>189</start><end>200</end><total>12</total></extent></part></relatedItem><identifier type="istex">12FB09FA70D0DDF0FBE1F765EB368C1299501042</identifier><identifier type="DOI">10.1111/j.1600-0404.1976.tb04337.x</identifier><identifier type="ArticleID">ANE189</identifier><accessCondition type="use and reproduction" contentType="copyright">1976 Blackwell Munksgaard</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000A18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:12FB09FA70D0DDF0FBE1F765EB368C1299501042
|texte= EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL
}}
| This area was generated with Dilib version V0.6.23. |  |